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Abstract 
Background: Opioid use disorder (OUD) affects approximately 21.9 million people worldwide. This study aims to 
determine the association between age of onset of opioid use and comorbid disorders, both physical and psychiatric, 
in patients receiving methadone maintenance treatment (MMT) for OUD. Understanding this association may inform 
clinical practice about important prognostic factors of patients on MMT, enabling clinicians to identify high-risk 
patients.
Methods: This study includes data collected between June 2011 and August 2016 for the Genetics of Opioid Addic-
tion research collaborative between McMaster University and the Canadian Addiction Treatment Centers. All patients 
were interviewed by trained health professionals using the Mini-International Neuropsychiatric Interview and case 
report forms. Physical comorbidities were verified using patients’ electronic medical records. A multi-variable logistic 
regression model was constructed to determine the strength of the association between age of onset of opioid use 
and the presence of physical or psychiatric comorbidity while adjusting for current age, sex, body mass index, metha-
done dose and smoking status.
Results: Data from 627 MMT patients with a mean age of 38.8 years (SD = 11.07) were analyzed. Individuals with an 
age of onset of opioid use younger than 18 years were found to be at higher odds for having a physical or psychiatric 
comorbid disorder compared to individuals with an age of onset of opioid use of 31 years or older (odds ratio 2.94, 
95% confidence interval 1.20, 7.19, p = 0.02). A significant association was not found between the risk of having a 
comorbidity and an age of onset of opioid use between 18 and 25 years or 26 and 30 years, compared to an age of 
onset of opioid use of 31 years or older.
Conclusion: Our study demonstrates that the younger one begins to use opioids, the greater their chance of having 
a physical or psychiatric co-morbidity. Understanding the risk posed by an earlier onset of opioid use for the later 
development of comorbid disorders informs clinical practice about important prognostic predictors and aids in the 
identification of high-risk patients.
Keywords: Opioid use disorder, Risk prediction, Substance use, Methadone, Opioid substitution treatment
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
Addiction Science & 
Clinical Practice
*Correspondence:  samaanz@mcmaster.ca 
†Leen Naji and Brittany Burns Dennis contributed equally to this work 
12 Department of Psychiatry and Behavioural Neuroscience, McMaster 
University, 100 West 5th Street, Hamilton, ON L8N 3K7, Canada
Full list of author information is available at the end of the article
Page 2 of 7Naji et al. Addict Sci Clin Pract  (2017) 12:9 
Background
Opioid use disorder (OUD) is a serious health concern 
associated with significant morbidity and mortality [1]. 
It is the second most prevalent illicit drug use disorder, 
affecting approximately 21.9 million people worldwide 
[1]. Despite evidence that the prevalence of pain has 
remained unchanged, the rate of opioid prescriptions has 
nearly quadrupled since 1999 [2]. Estimates based on The 
National Survey on Drug Use and Health indicate that 
12.5 million people in the United States alone misused 
opioids in 2015, in addition to the 0.8 million people who 
misused heroin that year [3].
Previous research demonstrates a potential predictive 
association between the use of opioids and the presence 
of comorbidities, likely secondary to a variety of factors 
including chronic intoxication, poor hygiene, life style 
habits and risk-taking behavior [4–17]. For instance, the 
prevalence of human immunodeficiency virus (HIV) 
is found to be higher among opioid users compared to 
non-users, as is the prevalence of infections such as hep-
atitis and tuberculosis [16, 18, 19]. Several studies have 
also linked opioid use to serious cardiac abnormalities, 
such as infective endocarditis, and a higher rate of epi-
leptic seizures [5, 6, 9, 13]. Additionally, opioid use has 
been associated with chronic pain, liver disease and men-
tal health comorbidities, such as depression and anxiety 
disorders [4, 10, 12]. While these studies do not establish 
causation, potential pathophysiological processes con-
tributing to the development of these comorbidities may 
be hypothesized. For instance, while infectious diseases 
may be associated with injecting drug use and risk-taking 
behavior, the neurological abnormalities are likely due 
to the neurotoxic effects of drug use leading to cerebral 
lesions [15].
Understanding the association between age of onset 
of opioid use and the presence of physical or psychiat-
ric comorbidity has seldom been the primary focus of 
previous studies. While addiction medicine clinicians 
may argue that pretreatment opioid use history seems 
logically inherent as a predictor for future health com-
plications, there is a paucity of well-powered studies to 
support such claims [5, 11, 15, 17, 20]. The rare times this 
issue is addressed in the literature, the primary focus is 
often the correlation between long substance use his-
tory and neurological deficits or infectious diseases. For 
instance, studies have demonstrated neurological abnor-
malities such as epilepsy, polyneuropathy, and pressure 
palsy increased with the duration of opioid use disorder 
[15]. Additionally, some studies have found an associa-
tion between the duration of heroin use and the presence 
of comorbidities, including HIV and hepatitis C [17, 20].
Nevertheless, no study to date has addressed nor quan-
tified the risk between age of onset of opioid use and the 
presence of physical or psychiatric comorbidities. Thus, 
the purpose of this study is to investigate this association 
using data from an on-going prospective cohort study. 
Understanding the association between the age of onset 
of opioid use and the presence of comorbid disorders 
informs clinical practice about important prognostic fac-
tors, enabling clinicians to identify high-risk patients. 
The opportunity to identify these patients would allow 
us to monitor them more closely, provide more intensive 
treatment strategies as well as preventative measures to 
reduce the risk of them developing a disease and/or pro-
gressing in their course of illness. These findings may 
also help to educate the public on the risks of opioid use 
above and beyond the direct effects of drug use, as well 
as identify modifiable factors that may increase the future 
risk of comorbidity in patients with OUD.
Methods
This study was approved by the Hamilton Integrated 
Research Ethics Board (11-056). We used data col-
lected primarily for the Genetics of Opioid Addiction 
(GENOA), a research collaborative between the Cana-
dian Addiction Treatment Center (CATC, formerly 
known as the Ontario Addition Treatment Centre and 
home to the largest network of methadone clinics in 
North America) and McMaster University [21]. CATC 
clinical sites follow the same treatment strategy and are 
managed centrally. In order to be included in our study, 
participants had to be 18  years of age or older, had to 
provide written informed consent, and had to have been 
receiving methadone maintenance treatment (MMT) 
for OUD as defined in the Fifth Edition of the diagnos-
tic and statistical manual of mental disorders (DSM-5) 
[22]. All study participants were interviewed by trained 
health care professionals between June 2011 and August 
2016. Previously piloted case report forms were used to 
obtain patient data, and physical comorbidities were con-
firmed using patients’ electronic medical records [21]. To 
be included, participants must have also completed the 
Mini-International Neuropsychiatric Interview (M.I.N.I.) 
at the time of inclusion into the study, which was used to 
determine psychiatric comorbidities [23]. For this study, 
683 patients met the eligibility criteria for inclusion 
(Fig. 1).
Our primary outcome was the composite of a physical 
or psychiatric co-morbid disorder. Physical comorbidi-
ties were identified through self-report and patients’ elec-
tronic medical records, and included HIV, hepatitis, liver 
disease, chronic pain and epilepsy, among others. Psychi-
atric diagnoses were ascertained based on the M.I.N.I. 
Patients were also required to complete a baseline ques-
tionnaire, providing details about their age of onset of 
opioid use, the duration of time they have been receiving 
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MMT and their current methadone dose, prescribed and 
non-prescribed medications, as well as illicit substance 
use [21].
Statistical analysis
We used descriptive statistics to summarize the par-
ticipants’ demographic and baseline characteristics. 
We expressed continuous variables using mean [stand-
ard deviation (SD)] and categorical variables using per-
cent. We performed the primary analysis by regressing 
the presence of a physical or psychiatric comorbidity, 
as composite outcome, onto the age of onset of opi-
oid use after categorizing age of onset of opioid use 
into four categories: Children: 17  years and younger 
(n =  119), youth: 18–25 years of age (n =  244), young 
adults: 26–30 years of age (n = 97), and 31 years of age 
and older (n = 167). We conducted the regression such 
that each category is compared to the reference group 
of 31  years of age and older. We adjusted for impor-
tant potential cofounders, specifically current age, sex, 
methadone dose, BMI and smoking status. Older age is 
known to be associated with more comorbidities [24]. 
Additionally, the prevalence of many psychiatric disor-
ders such as depression and physical comorbidities such 
as chronic pain are more prevalent in women than men 
[25–31]. High doses of methadone are associated with 
prolonged QTc intervals and arrhythmias such as Tor-
sades de pointes [32, 33]. Smokers and obese individuals 
are also at heightened risk for numerous serious comor-
bidities, including coronary artery disease and strokes 
[34, 35].
We performed secondary analyses investigating the 
association between the age of onset of opioid use and 
the presence of physical or psychiatric comorbidity, sepa-
rately, while still adjusting for the aforementioned covari-
ates as in the primary analysis.
We employed Stata 13 to complete the logistic regres-
sion analyses [36]. All study data have been quality 
checked and entered into Research Electronic Data Cap-
ture (RedCap) database at the Population Genomics Pro-




Of the 683 participants eligible for inclusion into our 
study, those with missing values for one or more of the 
covariates analyzed were dropped from the analysis 
(n  =  56). Therefore, we analyzed data from 627 sub-
jects. Please refer to Fig.  1 for the participants’ inclu-
sion diagram. The mean current age of participants was 
38.8  years (SD  =  11.1), more than half of whom were 
males (54.9%) (Table  1). The mean age of onset of opi-
oid use was 25.6  years (SD =  8.8). The majority of par-
ticipants (86.3%) had at least one comorbid physical or 
psychiatric disorder. Most (68.3%) participants were 
found to have at least one comorbid physical disorder, 
with chronic pain and hepatitis being the most common 
comorbidities (40.2 and 22.5% of participants, respec-
tively). Additionally, 57.7% of participants were diag-
nosed with a psychiatric disorder, the majority of which 
constituted an anxiety disorder (33.8% of participants).
Preliminary Screening for GENOA:
Men and women, age ≥18 years who are able to provide 
written informed consent, are receiving MMT for the 
treatment of OUD, and have completed the M.I.N.I. 
Resulted in 683 participants 
56 Participants excluded for having missing data in one or more 
the covariates included in the analysis
Resulted in 627 participants being included in the analysis
Fig. 1 GENOA: eligibility screening and inclusion flow diagram for participant selection
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Primary outcome
We determined the strength of the association between 
age of onset of opioid use and the presence of physical 
or psychiatric comorbidity using a multi-variable logis-
tic regression model. A summary of our results is pro-
vided in Table  2. Younger age of onset was significantly 
correlated to the presence of a physical or psychiatric 
comorbidity, when adjusting for current age, sex, BMI, 
methadone dose and smoking status (Table  2). These 
results indicate that the risk of comorbidity is highest in 
those who started using opioids before 18  years of age, 
as they were almost three-fold more likely of to have a 
physical or psychiatric comorbidity compared to those 
who began using opioids at the age of 31 and older (odds 
ratio (OR) 2.94, 95% confidence interval (CI) 1.20, 7.19, 
p  =  0.02). As expected, current age was also found to 
be significantly associated with physical or psychiatric 
comorbidity, implying that older individuals are at higher 
risk for the presence of a comorbidity (OR 1.05, 95% CI 
1.02, 1.08, p < 0.01). Finally, women were more likely to 
have a physical or psychiatric comorbidity than men (OR 
1.70, 95% CI 1.04, 2.75, p = 0.03).
Of note, our secondary analyses revealed that an age of 
onset of opioid use of younger than 18 years of age was 
significantly associated with an increased risk of having 
both a physical (OR 2.39, 95% CI 1.18, 4.85, p = 0.02) and 
psychiatric (OR 1.97, 95% CI 1.14, 3.40, p = 0.02) comor-
bidity, compared to those who began using opioids after 
the age of 30.
Discussion
Our study revealed that within a sample of patients 
receiving MMT for OUD, there exists a significant asso-
ciation between the age of onset of opioid use and the 
presence of one or more psychiatric or physical comor-
bidity, including but not limited to anxiety disorder, 
chronic pain, liver disease, epilepsy, HIV and hepatitis. 
In other words, our study demonstrates that within this 
population, the younger one begins to use opioids, the 
greater their chance of having a physical or psychiatric 
co-morbidity.
If an earlier age of onset of opioid use is assumed to 
implicate a longer duration of substance use, the find-
ings of our present study would be in accordance with 
the limited available literature investigating the associa-
tion between duration of opioid use and the presence of a 
physical comorbidity [5, 11, 15, 17]. These investigations 
have found a positive association between duration of 
opioid use and the presence of neurological abnormali-
ties or an HCV positive status [5, 11, 15, 17].
Table 1 Baseline participant characteristics (total N = 627)
a The physical comorbidities comprising the composite outcome included 
chronic pain (n = 252), epilepsy (n = 16), hepatitis (n = 141), liver disease 
(n = 31), HIV (n = 3), pulmonary disorders such as asthma and chronic 
obstructive pulmonary disorder (n = 52), diabetes mellitus type I or type II 
(n = 33), cardiovascular history including hypertension or cardiomyopathy 
(n = 33), arthritis (n = 25), inflammatory bowel disease (n = 6), endocrine 
disorders including hypothyroidism and hyperthyroidism (n = 15), cancer 
(n = 6), renal disorders (n = 5), neurological disorders including neuropathies 
and multiple sclerosis (n = 20), endometriosis (n = 7), dermatological disorders 
including eczema and psoriasis (n = 2), inactive TB (n = 2), and syphilis (n = 1)
b The psychiatric comorbidities comprising the composite outcome included 
mood disorders such as depression and mania (n = 87), anxiety disorders such 
as generalized anxiety and obsessive compulsive disorder (n = 212), substance 
use disorders other than opioids (n = 83), psychotic disorders (n = 24), eating 
disorders (n = 4), antisocial personality disorder (n = 144)
Mean (SD) Median (IQR)
Participant characteristic
 Current age (years) 38.8 (11.1) 37.0 (19.0)
 Methadone dose (mg/day) 77.24 (46.10) 70.00 (55.00)
 Age of onset of opioid use (years) 25.6 (8.8) 24.0 (13.0)
 BMI (kg/m2) 27.92 (8.88) 26.03 (7.76)
Percentage of total (N)
Female 45.1 (283)
Current smoking 84.5 (530)
Participants with ≥1 comorbidity 86.3 (541)
Participants with physical comorbiditya 68.3 (428)
Participants with psychiatric comorbidityb 57.7 (362)
Age of onset of opioid use categories
 17 years and younger 19.0 (119)
 18–25 years 38.9 (244)
 26–30 years 15.5 (97)
 31 years and older 26.6 (167)
Table 2 Multivariable logistic regression analysis: the 
presence of physical or psychiatric comorbidity (N = 627)
56 eligible participants were excluded from the multi-variable regression 
analysis for having missing values for one or more of the covariates of interest. 
As such, 167, 97, 244 and 119 patients from the 31 years and older, 26–30 years, 
18–25 years, and 17 years and younger subgroups were included in the analysis, 
respectively
* <0.01 = 0.002




 Current age (years) 1.05 (1.02, 1.08) <0.01*
 Sex 1.70 (1.04, 2.75) 0.03
 BMI 1.02 (0.99, 1.06) 0.19
 Methadone dose  
(mg/day)
1.00 (1.00, 1.01) 0.77
 Smoking status 1.56 (0.85, 2.88) 0.15
Age of onset of opioid use categories  
(in reference to 31 years and older)
 17 years old and younger 2.94 (1.20, 7.19) 0.02
 18–25 years 1.71 (0.83, 3.51) 0.14
 26–30 years 2.05 (0.89, 4.74) 0.09
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Additionally, our study is the first to quantify the associa-
tion between the odds of having comorbidity and the age 
of onset of opioid use. Our results demonstrate that an age 
of onset of opioid use younger than 18 years of age is sig-
nificantly associated with an increased likelihood of hav-
ing a psychiatric comorbidity, compared to an age of onset 
beyond 30. Though we cannot claim causality due to the 
cross-sectional design of this study, the association between 
psychiatric comorbidity and a younger age of onset of opi-
oid use may be explained by the fact that adolescence rep-
resents a period of time in which the brain is subject to 
critical neurochemical and functional changes, as well as 
maturing behavior and cognition [38]. Psychosocial and 
environmental factors, including drug use, are thought to 
interfere with this stage of development and may ultimately 
impact mental health [39]. Additionally, there exists a body 
of evidence that supports the presence of a positive corre-
lation between drug use, including opioids, and psychiatric 
comorbidities other than substance use disorder [40–42].
Moreover, our study found that women with OUD were 
more likely than men to have a physical or psychiatric 
comorbidity. This is consistent with previously published 
literature which has found that women are more severely 
affected by the deleterious effects of drug use on physical 
and mental health [26, 29]. This may be explained by the 
fact many psychiatric disorders, including major depres-
sion and generalized anxiety disorder, are more prevalent 
in women than men in the general population [25, 27, 
28]. As well, a study by Grella et al. [28] has found that 
this difference in prevalence is accentuated in patients 
with OUD. Moreover, chronic pain, which is the most 
prevalent physical comorbidity included in our compos-
ite outcome, is also more commonly found in women 
than in men in the general population [30, 31].
This study adds to the field of addiction by addressing 
age of onset of opioid use as a risk factor for concurrent 
physical ailments and psychiatric disorders in patients 
with OUD on MMT. Several factors render our study 
unique amongst the available literature on this topic, 
allowing us to draw more reliable conclusions from our 
findings. This study included a large sample size of a clin-
ical population receiving standardized MMT across mul-
tiple different sites. Second, our investigation obtained an 
older sample of participants, where the mean age of par-
ticipants was 38.8 years. This is in contrast to the avail-
able literature, which primarily focuses on opioid users in 
their mid-twenties [5, 11, 14, 15, 17]. Studying an older 
age group provides us with the opportunity to gain a bet-
ter understanding of the risks associated with a longer 
duration of opioid use, as well as a better chance of iden-
tifying physical and psychiatric comorbidities that may 
not be captured in a younger cohort.
Limitations
There are specific limitations of studying OUD, one 
being the multifaceted nature of addiction itself. There 
are numerous ways in which confounding can inevitably 
influence the results obtained during this study. OUD 
involves a complex network of variables all of which una-
voidably modify individual patient health outcomes. It is 
important to note that this study has taken time to out-
line the most important confounders and adjust for them, 
however the complex social conditions which surround 
each individual patient can as might be expected, be con-
strued as a primary contributor to their health outcome. 
We acknowledge that these exposures investigated in this 
study are only a piece of the larger network of factors that 
impact OUD patients’ health outcomes.
Additionally, the cross sectional nature of this study 
is a factor that may compromise the quality of the evi-
dence obtained. We are unable to establish a tempo-
ral relationship between the age of onset of opioid use 
and the presence of comorbid disorders. An inception 
cohort study design would be ideal to establish the age 
of onset of opioid use and ensuring all participants were 
free of physical and psychiatric comorbidity at baseline. 
However, following patients from the onset of opioid 
use onto the development of addiction may prove both 
unethical and unfeasible given the need for early inter-
vention if addiction is suspected and the potential high 
attrition rate.
Finally, our comorbidity outcome was dichotomized 
which may take away from the magnitude of the burden 
of certain diseases. Now that we have established that an 
association does exist, we encourage future research to 
investigate the association between age of onset of opi-
oid use and 10-year mortality risk or quality of life, using 
surrogate outcomes such as the Charlson Comorbidity 
Index [43].
Conclusion
Our study identified a significant association between age 
of onset of opioid use and the presence of a physical or 
psychiatric comorbidity in patients receiving MMT for 
OUD. Specifically, a younger age of onset was found to be 
associated with an increased likelihood of having a physi-
cal and/or psychiatric comorbidity. The results of this 
study may serve to enhance therapeutic guidelines for 
patients receiving MMT by identifying high-risk patient 
groups and addressing them accordingly. The opportu-
nity to identify these patients would allow us to moni-
tor them more closely, provide more intensive treatment 
strategies as well as implement preventative measures to 
reduce the risk of them developing a disease and/or pro-
gressing in their course of illness.
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